Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Renaissance Pharma Acquires Denavir Assets | Contract Pharma

What are you searching for?

Sign in
Breaking News

Renaissance Pharma Acquires Denavir Assets

Launches Prestium Pharma to manufacture and market in the U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Renaissance Pharma has acquired certain assets and the U.S. rights to manufacture, market and sell Denavir  (1% penciclovir cream), from Deerfield Management Co. and New American Therapeutics, a Deerfield portfolio company. Denavir is a topical antiviral for the treatment of recurrent cold sores. 
 
With the acquisition of Denavir, Renaissance has established a new subsidiary, Prestium Pharma, focused on commercializing branded products in the U.S. John Denman will serve as general manager of Prestium. Mr. Denman has more than 25 years of experience. Before joining the company, he held positions of increasing responsibility at Teva Pharmaceuticals and most recently was responsible for all aspects of its U.S. commercial operations including sales, marketing, R&D, and business development. Prior to Teva, Mr. Denman held a senior marketing position at Sandoz.
 
Pierre Frechette, president and chief executive officer of Renaissance, said, “We are enthusiastic about the acquisition of our first branded product and the creation of Prestium, and look forward to further expanding our product portfolio.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters